Bone marrow samples from 43 adult patients with de novo diagnosed acute myeloid leukemia (AML) -10 acute promyelocytic leukemias (APL) with t(15;17), four AML with inv(16), seven monocytic leukemias and 22 nonmonocytic leukemiaswere analyzed using high-density oligonucleotide microarrays. Hierarchical clustering analysis segregated APL, AML with inv(16), monocytic leukemias and the remaining AML into separate groups. A set of only 21 genes was able to assign AML to one of these three classes: APL, inv(16) and other AML subtype without a specific translocation. Quantitative RT-PCR performed for 18 out of these predictor genes confirmed microarray results. APL expressed high levels of FGF13 and FGFR1 as well as two potent angiogenic factors, HGF and VEGF. AML with inv(16) showed an upregulation of MYH11 and a downregulation of a gene encoding a core-binding factor protein, RUNX3. Genes involved in cell adhesion represented the most altered functional category in monocytic leukemias. Two major groups emerged from the remaining 22 AML: cluster A with 10 samples and cluster B with 12. All the eight leukemias that were either refractory to treatment or that relapsed afterwards were assigned to cluster B. In the latter cluster, CD34 upregulation and serine proteases downregulation is consistent with a maturation arrest and lack of granulocytic differentiation.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous group of hematological cancer with marked differences in their response to chemotherapy. As in many other human cancers, the diagnosis and classification of AML have been based on morphological, cytochemical and immunophenotypic features. More recently, genetic features have contributed to define biologically homogeneous entities inside AML. Thus, the WHO classification of the myeloid neoplasm has incorporated the information provided by all these specialities into the categorization of AML. 1 Karyotype is the most important independent prognostic factor and therefore the most useful parameter for stratifying patients into risk groups. Thus, the favorable outcome group is composed of well-defined subtypes in terms of cytogenetics: t(15;17), inv (16) and t (8;21) . 2, 3 In contrast, the correlation between morphologic characteristics, genetic abnormalities and prognostic features is more inconsistent in the remaining AML. Analysis of gene expression profiles (GEP) of tumors using microarray technology has become a powerful tool for classifying hematopoietic neoplasms. 4 Regarding AML, global gene expression patterns have demonstrated that wellrecognized cytogenetically groups correlate with specific GEP. [5] [6] [7] [8] [9] [10] [11] [12] In the present study, our first goal was to evaluate the capacity of GEP, analyzed by microarrays, for identifying different subclasses of AML. For this purpose, we have chosen a series of AML patients well characterized according to morphological, immunophenotypical and cytogenetic markers. This series included APL and AML with inv (16) cases as well as a cohort of patients corresponding to different morphological subtypes without recurrent chromosomal abnormalities (most of them with a normal karyotype) and without an accurate prognostic prediction. Our second goal was to dissect those genes that were differentially expressed in each AML group, focusing especially on those potentially involved in AML pathogenesis and molecular targets which were candidates for therapeutic intervention. Microarray results were validated with real-time quantitative PCR (RQ-PCR) in order to improve the reliability of the study.
Patients and methods

Patients
Bone marrow (BM) samples from 43 adult patients with newly de novo diagnosed AML were analyzed. In order to avoid misleading results because of normal cell contamination, only samples containing more than 80% blast cells were included in the study. 13 The median age was 36 years (range 14-70 years). Patients were classified according to the WHO classification into four subgroups: (a) 10 APL with t (15;17) confirmed by FISH studies with LSI PML/RARA probe (Vysis, Stuttgart, Germany), three of them had cytogenetic additional abnormalities and in two cases an insertion of the RARa gene into the PML gene was identified (Table 1) ; (b) four AML with inv (16) confirmed by FISH analysis with LSI CBFB probe (Vysis); (c) seven acute monocytic leukemias and (d) 22 nonmonocytic AML without recurrent cytogenetic translocations, 11 of them with normal karyotype. FISH analysis with LSI MLL probe (Vysis) was performed to exclude the presence of MLL rearrangements in all samples except APL and AML with inv(16) cases, and monosomy 7 was ruled out using CEP 7 probe (Vysis) in those patients with unsuccessful karyotype. Analyses of FLT3 status (internal tandem duplication -ITD -and activation loop mutations in tyrosine kinase domain) were performed in 36 out of the 43 AML patients as previously described.
14 Clinical and biological features are shown in Table 1 . All patients were treated with chemotherapy according to protocols of the Spanish PETHEMA Cooperative Group (APL-96, AML-99). 15 Three BM samples from healthy donors were also included as a control group. The study was approved by the local research ethics committee and written informed consent was obtained from all patients and healthy donors.
RNA isolation, labeling and microarray hybridization
Total RNA was extracted using Trizol reagent (Life Technologies, Gaithersburg, MD, USA) and purified with RNeasy Mini Kit (Quiagen, Valencia, CA, USA). The RNA integrity was assessed using Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA, USA). Double-stranded cDNA and afterwards biotinylated cRNA were synthesized using a T7-polyT primer and the BioArray RNA labeling kit (Enzo, Farmingdale, NY, USA), respectively. The labeled RNA was then fragmented and hybridized to HU-133A oligonucleotide array (Affymetrix, Santa Clara, CA, USA), which contained 22 283 probe sets, according to Affymetrix protocols. The arrays were scanned using the Gene Array Scanner (Affymetrix). Full microarray data compliant with the MIAME guidelines (http://www.mged.org/) are available at the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/, Accession Number GSE1729).
GeneChip data analysis
Data preprocessing: Expression value for each probe set was calculated using the MAS 5.0. software (Affymetrix). All samples had a scaling factor lower than threefold and a 3 0 /5 0 of GAPDH probe set o2.5. Gene expression levels were transformed to base two logarithms. A median normalization approach was applied. Genes with at least three 'Present' calls across all samples were selected.
Unsupervised cluster analysis: Hierarchical clustering
(Cluster and TreeView software) based on the average-linkage method with the centered correlation metric was used. 16 Multidimensional scaling method (BRB Array Tools version 3.0) was performed using Euclidean distance.
17
Supervised SAM analysis: Supervised learning was used in two ways: one, to identify genes with statistically significant changes in expression between different classes, and the other, to build a classifier that allowed us to predict the label of unknown samples accurately. In order to gain more reliability, two algorithms were used for each aforementioned task. For the first one, 'Significant Analysis of Microarrays' (SAM) algorithm was used. 18 All data were permutated over 100 cycles by using the two class (unpaired) and multiclass response format. Significant genes were selected based on the lowest false discovery ratio (FDR) (between 0.6 and 0.9). Moreover, a nonparametric tests such as Wilcoxon rank sum test (WRS) and Kruskal-Wallis test to compare more than two unpaired groups were used (SPSS 11.0, SPSS Inc.).
Class prediction supervised methodology: (1) A class predictor was carried out using a weighted voting algorithm and evaluated using leave-one-out crossvalidation. 4 (2) Prediction analysis of microarrays (PAM, R) by using the nearest shrunken centroids was carried out to identify subsets of genes that best characterized each class. 19 (3) Support vector machine algorithm (Gist package) was applied using multiple diagonal factor settings and hold-one-out crossvalidation in which one sample is held out from the SVM during training and subsequently given to the machine as a test sample. 20 
RQ-PCR
cDNAs obtained from the same samples analyzed by microarrays were used for RQ-PCR. The primer pairs used for each gene are given in Supplementary Table 1 . PCR reactions were performed in an iCycler Thermal Cycler (PROMEGA, Madison, WI, USA) using SYBR Green dye. 21 The expression of housekeeping gene ABL was used to normalize the expression data. A relative standard curve representing four 10-fold serial dilutions (100, 10, 1 and 0.1 ng) of cDNA from one normal bone marrow was constructed. A melting curve analysis was performed in order to evaluate whether specific PCR products had been formed.
Results
Unsupervised analysis of the AML samples
In an initial approach of the gene expression data set (1 025 018 measurements, 22 283 probe sets in 46 samples), we explored the separation of the samples into clusters based on similarities in gene expression by using hierarchical cluster analysis and multidimensional scaling. A two-dimensional hierarchical clustering analysis performed on 5670 genes passing the variation filter showed a dendogram with two major branches: in one branch the inv(16) group, monocytic leukemia group and the three BM controls could be identified as separate clusters, while the second branch was divided into two sub-branches, one containing all APL samples which were all clustered next to one another and the other containing 17 samples corresponding to other subtypes of AML. Since normal BM samples did not segregate into a cluster completely separated from the leukemic samples and the dendogram excluding the BM controls maintained a similar structure (Figure 1 ), the normal controls were not considered in the subsequent analysis. When we used multidimensional scaling analysis, the APL samples were the most tightly clustered, even though the inv (16) and monocytic leukemias were also located into well-defined groups. No specific clusters were detected according to chromosomal abnormalities other than t(15;17) and inv (16) .
Supervised analysis of the AML samples
The second approach was to investigate the minimum number of genes that would provide a better discrimination among three classes: two cytogenetically well-defined AML subtypes associated with good prognosis, APL and inv (16) , and the remaining Figure 1 Dendogram from a hierarchical cluster analysis of the 43 AML samples based on the expression of 5670 genes passing a variation filter generated by using Cluster and TreeView programs. Horizontal bars along the dendogram represent four morphological and/or cytogenetic clusters.
AML cases. For this supervised purpose, firstly, a class prediction methodology using a training set of 43 AML samples (10 APL, four inv(16) and 29 'other subtypes') and a leave-one-out crossvalidation scheme were used. The predictor contained a minimum of 21 genes and assigned the withheld sample to the appropriate class with 100% accuracy. We confirmed these results by using nearest shrunken centroids method (PAM software) with an independent test set: a training group with 25 samples out of the total of 43 samples (five APL, three inv(16) and 17 'other subtypes') and a test group with the remaining 18 samples (five APL, one inv(16) and 12 'other subtypes') were defined. This analysis found that only a set of 23 genes (identified by 26 probe sets) was able to assign each AML to one of the three classes: APL, inv (16) and 'other subtypes' (Figure 2 ). The accuracy of this model was assessed by the test samples, which were correctly classified with 100% accuracy. We also applied the SVM algorithm to discriminate APL from inv (16) , APL from 'other subtypes' and inv(16) from 'other subtypes'. This method correctly classified all samples in each class of these three binary sets using the features selected by SAM: 124, 381 and 39 features in the APL/inv(16), the APL/ 'other subtypes' and the inv(16)/'other subtypes' comparisons respectively. To confirm that the microarray analysis provided an accurate reflection of gene expression levels, we compared the microarray data from 18 out of the predictor genes with RNA levels obtained by RQ-PCR for a subset of samples. A substantial agreement between the relative expression levels obtained from both assays was found (Supplementary Figure 1) .
Gene expression profiling of APL
Genes distinguishing the APL from the rest of AML (non-APL) were identified as significant by the intersection of data sets from SAM and Wilcoxon rank sum tests. A total of 224 genes were overexpressed in APL and 158 genes were underexpressed as compared to non-APL.
APL samples expressed high levels of several growth factors, growth factor receptors and other proteins involved in signalling: hepatocyte growth factor (HGF) and genes related (MST1 and MSTP9), vascular endothelial growth factor (VEGF), insulinlike growth factor binding protein 2 (IGFBP2), growth factor receptor-bound protein 10 (GRB10), fibroblast growth factor 13 (FGF13) and fibroblast growth factor receptor 1 (FGFR1) which codes for a tyrosine kinase protein. In contrast, transforming growth factor beta 1 (TGFB1) was downregulated in APL 'Nearest-shrunken centroids' method was used to identify the genes that best characterize the three classes, AML with inv(16), APL and remaining AML cases. Shrunken differences for the 26 probe sets (23 genes) having at least one nonzero difference are depicted. Left-sided bars indicate lower expression in subgroups relative to overall centroid; right-sided bars indicate higher expression in subgroups relative to overall centroid. The genes with non-zero components in each class are almost mutually exclusive. The length of horizontal bars represents the difference between the overall centroid and each of the three subgroup centroids. Genes are ordered according to the greatest difference at the top and the smallest at the bottom. P-values (Kruskal-Wallis test) for difference between each group centroid and the overall centroid for all comparisons are indicated.
compared to most non-APL. FGF13 and HGF were the most significantly overexpressed genes in APL.
Deregulation of homeobox containing genes clearly differentiated APL from the non-APL. Members of HOX family (A5, A6, A7, A9, A10, B2, B5 and B7) and the TALE proteins (MEIS1 and PBX3) were jointly overexpressed in non-APL leukemias. PBX2 was expressed in all AML samples with an intensity level similar to controls while PBX1 expression was absent in all AML cases. Members of the histone family were mostly upregulated in non-APL as compared to APL.
In order to identify the genes that best discriminate APL from non-APL, a prediction algorithm was employed: a classifier involving as few as 11 genes proved to be 100% accurate in the APL/nonAPL distinction using a leave-one-out crossvalidation approach (Supplementary Figure 2) . Interestingly, we also had the opportunity to compare three distinct subsets within the APL cases: (1) classical APL with t(15;17), (2) patients with cryptic t(15;17) and (3) cases with additional cytogenetic abnormalities. However, supervised analysis failed to demonstrate differences in GEP between these three groups (data not shown). Likewise, the three APL cases with FLT3 mutations were not clustered and supervised analysis did not identify genes differently expressed in these patients.
Gene expression profiling of AML with inv(16)
AML with inv(16) were totally different from APL in genes whose expression was variable in the rest of AML samples and did not show a specific pattern (Supplementary Table 2) .
Noticeably, AML with inv (16) showed an elevated expression level of MYH11 isoform SM2 (smooth muscle myosin heavy chain 11), the CBFB fusion partner in the inv (16) . Regarding core-binding factor proteins, it is noteworthy that CBFB (16q22) and RUNX3, a tumor suppressor gene localized at 1p36, were downregulated in AML with inv (16) . CBFB was expressed in all AML samples but the expression levels were significantly lower in AML with inv(16). RUNX3, which was expressed in almost all AML samples, had an absent expression in AML with inv(16). However, RUNX1 (at 21q22) expression levels had similar intensity in all AML cases and were not reduced in AML with inv (16) . The other CBF member, RUNX2, was absent in all AML patients. In order to gain insight into expression levels of genes participating in CBFB-MYH11 fusion transcript, we designed a RQ-PCR with primers developed downstream of all known MYH11 fusion points (primers localized at exon 42) and upstream of all known CBFB fusion points (primers localized at exons 3 and 4). Both genes showed high levels of expression, as determined by RQ-PCR, in the four AML with inv (16) . On the other hand, the CBFB fragment not included in the CBFB-MYH11 fusion (primers localized at exon 6) showed low expression levels in a similar way to microarrays analysis since probe sets identifying CBFB corresponded to sequences contained mostly in this fragment. Furthermore, the MYH11 fragment not contained in the CBFB-MYH11 fusion transcript (primers localized at exons 2 and 3) showed expression levels comparable to those observed in other AML subtypes (Supplementary Figure 3 ).
Gene expression profiling of monocytic leukemia
Since monocytic AML samples were clustered together both in clustering analysis and in multidimensional scaling, we carried out a SAM analysis to define differentially expressed genes between the seven monocytic AML and the remaining 22 AML cases without recurrent abnormalities. A total of 224 genes were overexpressed in monocytic AML and only 28 genes were underexpressed compared to the remaining AML. The functional category, which was most significantly altered in monocytic leukemias compared to the remaining 22 AML samples, were the genes involved in cell adhesion. Thus, along with CSPG2, other adhesion molecules such as the lectins CLECSF6, CLECSF12, SIGLEC7 and FCN1 were upregulated.
Gene expression profiling of remaining AML
To gain more insight into the AML subclasses that were not grouped into clusters according to karyotype or morphological criteria, we submitted them (22 samples) to a two-dimensional hierarchical clustering analysis, which revealed again two major groups without any genetic (including FLT3 status) or morphological distribution: cluster A with 10 samples and cluster B with 12. All the eight leukemias that were refractory to treatment or that relapsed afterwards were assigned to cluster B (Supplementary Figure 4 ): relapse-free survival rate at 1 year was 33% for cluster B vs 100% for cluster A (P ¼ 0.01). Then, a supervised analysis with these two classes was performed and a total of 21 genes were significantly different between the two clusters (Supplementary Figure 4) : members of a family of neutrophil serine proteases, neutrophil elastase (ELA2), proteinase 3 (PRTN3), cathepsin G and the catalytically inactive azurocidin (AZU1) were included among the most significant genes upregulated in cluster A, whereas gene encoding for CD34 antigen was the only gene underexpressed in cluster A as compared to cluster B.
Discussion
Our results demonstrate that gene expression patterns in AML are significantly correlated with t(15;17) and inv(16) as well as monocytic leukemias. AML expression patterns have been linked to the cytogenetic features rather than to the morphological characteristics of AML blast cells. [5] [6] [7] [8] [9] [10] In contrast, in the present study, a specific expression pattern for monocytic AML independently of the chromosomal abnormalities was found. It should be noted that samples with normal karyotype did not segregate from those with nonrecurrent abnormalities. The normal cytogenetic group has been grouped into a distinct cluster in other study suggesting a particular expression pattern for normal karyotypes. 6 However, it should be expected that the normal karyotype behave like a heterogeneous category, remaining grouped when compared to well-defined translocations, but not when other rare abnormalities are included in the analysis. Thus, it is imperative to investigate gene expression profile in depth, in a larger number of AML samples without chromosomal abnormalities to unmask possible different subentities hidden under the normal karyotype. The expression differences between two AML subtypes with good prognosis -APL and AML with inv(16) -and the rest of AML samples were so robust that a small set of 21 genes was able to correctly classify 100% of the AML samples as one of these three classes. Furthermore, the power of discrimination of most of these genes was validated by RQ-PCR, which supports the potential applicability of the discriminating genes in a clinical setting.
The most significant overexpressed gene in the comparison between APL and non-APL cases was fibroblast growth factor 13 (FGF13). Fibroblast or heparin-binding growth factors (FGF) are potent regulators of cell growth and differentiation and play crucial roles in normal development. 22 FGF signalling occurs by activation of transmembrane tyrosine kinase receptors (FGFR1-4). Interestingly, FGFR1 was highly expressed in all APL and to a lesser extent in AML with inv(16) while expression was absent in almost all remaining AML. Although the oncogenic role of FGFR1 in the stem cell leukemia-lymphoma syndrome (SCLL) is well-established, little is known about the possible action of FGF13 (one of the last members of FGF family to be characterized) in a hemopoiesis context. [23] [24] [25] We have speculated that the FGF13/FGFR1 system could aberrantly activate tyrosine kinase function in APL blasts. At this point, research into the efficiency of binding of the FGF13-FGFR1 protein complex is necessary.
Hepatocyte growth factor (HGF) was the second most significant overexpressed gene in the comparison between APL and non-APL. HGF is a potent angiogenic factor and it has been involved in cancer invasion and metastasis of solid tumors and hence, it has been correlated with poor prognostic in a variety of solid tumors. 26 The significance of HGF in the pathogenesis of hematological malignancies has not been fully evaluated. It seems to be that plasma HGF levels are elevated in patients with newly diagnosed AML and MDS and it is associated with shorter survival in AML but not MDS patients. 27 Our work represents the first evidence for the high expression of HGF in APL and the lack of expression in all the non-APL and normal controls (Gutiérrez et al. Blood 2003; 102: abstract #70). This finding has been also reproduced in larger series. 8 The possible contribution of HGF to severe coagulopathy associated with APL still needs to be elucidated. An increased angiogenesis in the bone marrow of patients with APL has been demonstrated in previous studies and VEGF is believed to be the major positive mediator of angiogenesis. 28, 29 We also found a significant upregulation of VEGF in APL and this would support the notion that angiogenesis may have a critical role in the pathophysiology of APL. The fact that the ATRA therapy inhibits VEGF production and decreases microvessel density is consistent with this hypothesis. 28 Although disease-free survival rates in APL are greater than 80%, the possible associations of antiangiogenic agents and/or tyrosine kinase receptor inhibitors like SU5402 (anti-FGFR activity) could be an attractive strategy to improve outcomes in refractory patients. 30 One of the most important upregulated gene families in most of the non-APL cases in comparison with APL was the homeodomain containing genes, HOX genes and non-HOX genes (the TALE proteins PBX and MEIS), whose role in leukemic transformation has been convincingly demonstrated. [31] [32] [33] It has been suggested that HOX gene expression is activated by MLL rearrangements. 10, 34 However, MLL abnormalities were only present in four AML cases of our series (one of them showed an MLL rearrangement), which indicates that other genetic mechanisms irrespective of MLL fusion proteins could activate HOX genes, as has been suggested recently. 9 The expression levels of HOX family displayed the same behavior in AML with inv (16) as it did in APL except for HOXB2, which was upregulated on inv(16) at a similar level to the remaining leukemias.
The influence of additional abnormalities on the outcome of favorable prognosis cytogenetics has been a matter of controversy, although the most recent studies, which include large groups of patients, have not found a deleterious effect. 2, 3, 35 In line with this, our work does not show any difference in GEP between APL with and those without additional abnormalities. Furthermore, in our study, the two cases with cryptic t (15;17) due to an insertion of the RARa gene into the PML gene showed an identical GEP to classic t (15;17) . Nevertheless, these results are based on a small number of samples and need further confirmation.
One of the most interesting observations from GEP in AML with inv(16) was the deregulation of the genes involved in the inv(16) rearrangement. The overexpression of MYH11 detected in the present study has been already observed by using microarrays, [5] [6] [7] [8] but this finding was presumably attributed to hybridization of the specific fusion transcript CBFB-MYH11 to corresponding MYH11 sequences represented on the microarray. 5, 7 However, our RQ-PCR results exhibit that not only MYH11 fragment included in the CBFB-MYH11 fusion transcript, but also CBFB fragment are overexpressed. This finding demonstrates an overexpression of the whole CBFB-MYH11 mRNA, which has not been shown up until now. CBFB-MYH11 transcripts lose the AU-rich sequences contained at the 3 0 untranslated regions of CBFB which act as destabilizing motifs in many labile transcripts and it has been suggested that the loss of this sequence leads to a more stable mRNA and, hence, may contribute to a higher protein expression. 36, 37 This is in line with a study that proposes the use of RQ-PCR for MYH11, since it is upregulated, instead of RQ-PCR for CBFB-MYH11, in order to identify inv (16) in patients with AML. 38 A member of CBFA family, RUNX3, which was significantly downregulated in LAM with inv(16) has recently been described as a tumor suppressor in human gastric cancer although it is expressed predominantly in cells of hematopoietic origin. 39 The absent expression of this gene in AML with inv(16) might play an important role in hematopoietic leukemogenesis.
A striking finding was the separation of monocytic leukemias in a defined cluster showing a high degree of similarity in gene expression among this AML subtype, independently of cytogenetic status. These data indicate that morphological characteristics and the expression profile of monocytic blasts are not conferred by a particular chromosomal abnormality, suggesting that other more important genetic defects are driving the phenotypic fate of these blasts.
Undoubtedly, the most important challenge in AML is to categorize those cases with normal karyotypes or with chromosomal abnormalities other than translocations giving rise to fusion proteins. This heterogeneous group of AML is represented in our study by 22 samples (monocytic leukemias were excluded since this class comprised a stable cluster different from other AML cases), which were segregated into two clusters mainly based on the CD34 antigen and the hematopoietic serine protease (AZU1, ELA2, PRTN3 and cathepsin G) expression. A recent study has revealed a downregulation of these neutrophil proteases in therapy-related AML, which could be linked to an arrest of maturation in early progenitor cells of this type of AML. 12, 40 Although none of the patients included in our work have been previously treated with cytotoxic agents, the association of CD34 upregulation and serine proteases downregulation in one of the clusters is also consistent with a maturation arrest and lack of granulocytic differentiation. It is of interest that the eight patients out of 22 remaining AML, which were refractory to treatment or relapsed within 1 year from the first complete remission, were included in the same cluster. The group of differentially expressed proteases mentioned above has not been associated previously with clinical response in AML and should be explored in a larger cohort of patients in order to elucidate if they are responsible for a dismal prognosis.
Although karyotype at diagnosis provides the most important prognostic information in AML, other novel prognostic molecular markers such as FLT3 have merged as relevant outcome indicators. We investigated whether patients with FLT3 muta-tions (ITDs and D835 mutations) displayed a singular GEP, but, in accordance with previous reports, we did not find a molecular signature associated with this abnormality. 8, 9 Moreover, no correlation between the levels of FLT3 expression and FLT3 mutational status was found in our AML series as previously reported. 9 In summary, the present work reveals new deregulated genes in different subclasses of AML. Some of these genes may be directly implicated in the pathogenesis of AML and in addition, several of them encode for proteins, which are known therapeutic targets. Although we have not included any functional characterization of potential target genes, some deregulated genes shown in the present study open up the possibility for therapeutic intervention. Thus, the upregulation in APL of two major angiogenic factors, such as HGF and VEGF, suggests that angiogenesis may have an important role in this type of AML and therefore, the design of studies in order to explore the action of antiangiogenic agents in APL could be of interest. Likewise, the overexpression of FGF13 and that of one of its tyrosine kinase receptor (FGFR1) could lay the foundations for investigations into the effect of tyrosine kinase inhibitors in APL. Microarray technology is a useful tool in order to uncover previously unrecognized diversity among those less welldefined AML in terms of morphology or cytogenetics. More importantly, although further and extended studies leading to the evaluation of the prognostic significance of expression patterns are needed, this work points to the possibility of defining prognostic clusters based on gene expression profile.
